

Ref: Syn/CS/SE/Reg 30/January/2019-20/86

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099,
India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937
www.syngeneintl.com

January 22, 2020

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Intimation of Change in Key Managerial Personnel

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015

With reference to the captioned subject, we hereby inform that the Board of Directors at their Meeting held today have separated the roles of Managing Director and Chairperson with effect from April 01, 2020. Accordingly, Mr. Jonathan Hunt currently, Wholetime Director and Chief Executive Officer, will assume the position of Managing Director and Chief Executive Officer of the Company for a period of 5 years with effect from April 01, 2020, subject to approval of the shareholders.

Ms. Kiran Mazumdar Shaw will become the Non-Executive Chairperson of the Company with effect from April 01, 2020.

A brief profile of Mr. Jonathan Hunt is attached with this intimation.

Also, please find enclosed a press release in this regard.

We request you to kindly take this information on record and oblige.

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**



Priyadarshini Mahapatra
Company Secretary & Compliance Officer



Mr. Jonathan Hunt -Brief Profile



Mr. Jonathan Hunt holds a BA (Business Studies & Economics) degree from the University of Sheffield, United Kingdom and has done his MBA from Durham University, United Kingdom. He is responsible for leading Syngene's business operations as well as steering its investments in developing and strengthening its capabilities and capacities. He has more than 25 years of extensive experience in the global biopharmaceuticals industry.

Prior to joining Syngene in January 2015, he worked with AstraZeneca for over a decade where he has held various leadership positions including President & Director of AstraZeneca, Austria and President & COO, AstraZeneca India.

Mr. Jonathan Hunt is not related to any of the directors of the Company.

Syngene appoints Jonathan Hunt as Managing Director and Chief Executive Officer

Kiran Mazumdar Shaw becomes Non-Executive Chairperson

Bengaluru, 22nd January, 2020

The Board of Syngene International Limited has at its meeting held today announced the separation in roles of the Managing Director and Chairperson with effect from April 01, 2020. Accordingly, Mr. Jonathan Hunt, currently Whole-time Director and Chief Executive Officer, will assume the position of Managing Director and Chief Executive Officer of the Company and Ms. Kiran Mazumdar Shaw will become the Non-Executive Chairperson with effect from 1st April 2020.

Kiran Mazumdar Shaw, Managing Director, said “Over the past four years, under the leadership of Jonathan Hunt, Syngene has shown considerable growth while expanding its capabilities into new, emerging areas of research and development to meet the existing and future requirements of its clients. His track record demonstrates that he brings strong leadership, an ability to build sustainable partnerships with customers and a clear vision which will drive the Company’s next growth phase.”

Jonathan Hunt, Chief Executive Officer commented “It is an honour to be appointed as Managing Director and Chief Executive Officer of Syngene. The company is at the cusp of its next growth phase and I firmly believe that we have the right mix of scientific talent and world class technology, underpinned by a track record of quality and regulatory compliance, to achieve our ambitions. We are continuing to see increasing interest in outsourcing research and development among our customers. Against this backdrop, I believe the opportunities for Syngene are many and I am very pleased to be at the helm for the next phase.”

Syngene

Putting Science to Work

Confidentiality

Quality

Innovation

Science

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation-focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele includes world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000-strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed up time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com